The transaction is small and contingent; no material near-term catalyst for SPRC. Monitor for closing conditions (Israeli tax ruling, final TSX acceptance) by June 1, 2026. The deal does not change SciSparc's cash position or pipeline.
Price Chart
Executive Summary
SciSparc announced that its majority-owned subsidiary NeuroThera received conditional TSX approval for the acquisition of ~54% of CliniQuantum. The deal, valued at ~$9.46M in NeuroThera shares, has been extended to June 1, 2026, pending final conditions including an Israeli tax ruling. This is a small, contingent transaction with no direct financial impact on SciSparc's standalone operations.
Key Financial Metrics
Key Facts
- NeuroThera received conditional TSX approval to acquire ~54% of CliniQuantum for 56.6M NeuroThera shares valued at ~$9.46M.
- The outside date for closing was extended from April 30, 2026 to June 1, 2026.
- CliniQuantum holds a license for quantum simulation/Monte Carlo methods applied to clinical trial data analysis.
- SciSparc's market cap is ~$3M; the deal is contingent and non-transformative for SciSparc's core business.
Financial Impact
~$9.46M in NeuroThera shares issued for 54% of CliniQuantum; no cash consideration.
Risk Factors
- Transaction may not close if conditions (tax ruling, TSX final acceptance) are not met.
- Consideration shares issued at floor price of $0.05 could dilute NeuroThera shareholders.
- No direct revenue or earnings impact for SciSparc; limited upside catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers